Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression

Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ-mediated transport of TRKA

(2017) Stuart M. Fell et al.   GENES & DEVELOPMENT

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

(2016) Eli M. Wallace et al.   CANCER RESEARCH

Targeting renal cell carcinoma with a HIF-2 antagonist

(2016) Wenfang Chen et al.   NATURE

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

(2016) Hyejin Cho et al.   NATURE

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

(2016) Caroline Wigerup et al.   PHARMACOLOGY & THERAPEUTICS

Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth

(2016) Michael S. Nakazawa et al.   Nature Communications

DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

(2015) Olga Grishina et al.   BMC CANCER

DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights

(2015) Soledad Gómez et al.   Epigenomics

Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells

(2015) Flora Cimmino et al.   Scientific Reports

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

(2015)   Oncotarget

HIF2A and IGF2 Expression Correlates in Human Neuroblastoma Cells and Normal Immature Sympathetic Neuroblasts

(2015) Sofie Mohlin et al.   NEOPLASIA

Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes

(2014) Tamer E. Fandy et al.   CLINICAL CANCER RESEARCH

Prognostic Potential of DNA Methylation and Transcript Levels of HIF1A and EPAS1 in Colorectal Cancer

(2014) Agnieszka Anna Rawłuszko-Wieczorek et al.   MOLECULAR CANCER RESEARCH

Comprehensive analysis of DNA methylation data with RnBeads

(2014) Yassen Assenov et al.   NATURE METHODS

The Correlation of Expression Levels of HIF-1  and HIF-2  in Hepatocellular Carcinoma with Capsular Invasion, Portal Vein Tumor Thrombi and Patients' Clinical Outcome

(2013) S.-L. Yang et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas

(2013) Kiyoshi Asada et al.   JOURNAL OF HUMAN GENETICS

The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote

(2013) Yang Liao et al.   NUCLEIC ACIDS RESEARCH

Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma

(2013) H Kocak et al.   Cell Death & Disease

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data

(2012) Andrew E. Teschendorff et al.   BIOINFORMATICS

Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas

(2012) Nimrod B Kiss et al.   BMC Medical Genetics

Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis

(2012) Shizhen Zhu et al.   CANCER CELL

Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway

(2012) Hai-Xiang Sun et al.   HEPATOLOGY

Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma

(2012) D. K. Krishnadas et al.   PEDIATRICS

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers

(2012) Anneleen Decock et al.   GENOME BIOLOGY

Integration of CNS survival and differentiation by HIF2α

(2011) C-Y Ko et al.   CELL DEATH AND DIFFERENTIATION

Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1 

(2010) G. Qing et al.   CANCER RESEARCH

Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease

(2010) Barbara S. Paugh et al.   JOURNAL OF CLINICAL ONCOLOGY

A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients

(2010) Paolo Fardin et al.   Molecular Cancer

How does PKMζ maintain long-term memory?

(2010) Todd C. Sacktor   NATURE REVIEWS NEUROSCIENCE

HIF-2  deletion promotes Kras-driven lung tumor development

(2010) J. Mazumdar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset

(2010) H. Caren et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery

(2009) Chen-Xin Dai et al.   BMC CANCER

Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells

(2009) Zhizhong Li et al.   CANCER CELL

Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

(2009) L. A.M. Gravendeel et al.   CANCER RESEARCH

HIF-1  and HIF-2  Are Differentially Regulated In vivo in Neuroblastoma: High HIF-1  Correlates Negatively to Advanced Clinical Stage and Tumor Vascularization

(2009) R. Noguera et al.   CLINICAL CANCER RESEARCH

HIF2α cooperates with RAS to promote lung tumorigenesis in mice

(2009) William Y. Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

HIF-2  maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells

(2009) A. Pietras et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Abundance of Ubiquitously Expressed Genes Revealed by Tissue Transcriptome Sequence Data

(2009) Daniel Ramsköld et al.   PLoS Computational Biology

HIF-1α and HIF-2α have divergent roles in colon cancer

(2008) Takaaki Imamura et al.   INTERNATIONAL JOURNAL OF CANCER

The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

(2008) Tom Monclair et al.   JOURNAL OF CLINICAL ONCOLOGY